EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE

Inmaculada Martinez-Saguer, Andrea Zanichelli, Emel Aygören-Pürsün, Markus Mager, Aleena Banerji, Paula J Busse, Stephen D Betschel, Mauro Cancian, Tamar Kinaciyan, Aharon Kessel, M Dawn Goodyear, Daniel Nova Estepan und 5 weitere

Revista Alergia México · 2025

DOI: 10.29262/ram.v72i3.1505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Revista Alergia México, 2025. Verfasst von Inmaculada Martinez-Saguer und 16 weiteren Autor:innen. Beteiligte Einrichtung: Centro de Hemofilia HRZM Rhine Main, Fráncfort del Meno, Alemania. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Angioedemas, Hereditary. Die Arbeit nennt 10 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Methods: Patients with HAE type I/II, aged ≥12 years, were included from the EMPOWER and ENABLE studies, who received lanadelumab at the approved dose and had data on the initial attack rate. Subgroups were created based on baseline HAE activity (moderate: ≥1 to

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAngioedemas, HereditaryHumansMaleFemaleMiddle AgedAdultTreatment OutcomeAgedBroadly Neutralizing AntibodiesYoung AdultAdolescent

Stichwörter der Autor:innen

Disease activityEMPOWEREnableHereditary angioedemaLanadelumab

Substanzen

Antibodies, Monoclonal, HumanizedlanadelumabBroadly Neutralizing Antibodies

Autor:innen und Institutionen

  • Centro de Hemofilia HRZM Rhine Main, Fráncfort del Meno, Alemania.
  • Unidad Operativa de Medicina, Centro de Angioedema, IRCCS Policlínico San Donato, Milán, Italia y Departamento de Ciencias Biomédicas para la Salud, Universidad de Milán, Milán, Italia.
  • Departamento de Niños y Adolescentes, Centro de Angioedema, Hospital Universitario de Frankfurt, Universidad Goethe, Frankfurt, Alemania.
  • Instituto de Alergología, Charité-Universitätsmedizin Berlin (miembro corporativo de Freie Universität Berlin y Humboldt-Universität zu Berlin), Berlín, Alemania.
  • Departamento de Inmunología y Alergología, Instituto Fraunhofer de Medicina Traslacional y Farmacología ITMP, Berlín, Alemania.
  • División de Reumatología, Alergia e Inmunología, Departamento de Medicina. Hospital General de Massachusetts, Facultad de Medicina de Harvard, Boston, MA, EE. UU.

Zitieren

APA

Martinez-Saguer, I., Zanichelli, A., Aygören-Pürsün, E., Mager, M., Banerji, A., Busse, P. J., Betschel, S. D., Cancian, M., Kinaciyan, T., Kessel, A., Goodyear, M. D., Estepan, D. N., Andresen, I., Juethner, S., Khutoryansky, N., Wuillemin, W., & Rodriguez, J. C. (2025). Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE. Revista Alergia México. https://doi.org/10.29262/ram.v72i3.1505

Vancouver

Martinez-Saguer I, Zanichelli A, Aygören-Pürsün E, Mager M, Banerji A, Busse PJ, et al. Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE. Revista Alergia México. 2025. doi:10.29262/ram.v72i3.1505

BibTeX
@article{MartinezSaguer2025,
  author = {Martinez-Saguer, Inmaculada and Zanichelli, Andrea and Aygören-Pürsün, Emel and Mager, Markus and Banerji, Aleena and Busse, Paula J and Betschel, Stephen D and Cancian, Mauro and Kinaciyan, Tamar and Kessel, Aharon and Goodyear, M Dawn and Estepan, Daniel Nova and Andresen, Irmgard and Juethner, Salomé and Khutoryansky, Natalie and Wuillemin, Walter and Rodriguez, Juan Carlos},
  title = {Effectiveness and safety of Lanadelumab according to disease activity: pooled analysis of EMPOWER/ENABLE},
  journal = {Revista Alergia México},
  year = {2025},
  doi = {10.29262/ram.v72i3.1505}
}
Kostenlos starten →